Publication:
A Rare Variant of Glioblastoma Is Gliosarcoma: 11-Case Clinical Trial

dc.authorscopusid58971785200
dc.authorscopusid58972202500
dc.authorscopusid58971571000
dc.authorscopusid36463197200
dc.authorscopusid55936052000
dc.contributor.authorEngin, R.
dc.contributor.authorTomakin, F.
dc.contributor.authorGökalp, G.
dc.contributor.authorAras, M.
dc.contributor.authorÇokluk, C.
dc.date.accessioned2025-12-11T00:33:24Z
dc.date.issued2024
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Engin] Recai, Department of Neurosurgery, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaras, Kahramanmaraş, Turkey; [Tomakin] Fatih, Department of Neurosurgery, Unye State Hospital, Ordu, Ordu, Turkey; [Gökalp] Gürkan, Department of Neurosurgery, Ondokuz Mayis University, Medical School, Samsun, Turkey; [Aras] Mustafa, Department of Neurosurgery, Ondokuz Mayis University, Medical School, Samsun, Turkey; [Çokluk] Cengiz, Department of Neurosurgery, Ondokuz Mayis University, Medical School, Samsun, Turkeyen_US
dc.description.abstractGliosarcoma is a rare subtype of glioblastoma, IDH wild type. Its characteristic features are a biphasic configuration with mixed glial and mesenchymal components. Here in, we present a rare case of Gliosarcoma that has been operated in our clinic in the last 10 years. Patients with gliosarcoma pathology results were collected from the ones operated in our faculty within 10 years. Patients from all age groups were included in the study. 1 of 11 gliosarcoma cases was described in detail. Seven of the cases were male, while 4 were female. Regarding tumor location, six 6 were located in the right, while 5 were in the left hemisphere. The average survival time of all 11 patients was 11 months. In 6 cases, the initial pathologic diagnosis was gliosarcoma, while in 5 cases, it was glioblastoma, and in the 2nd case, the pathology result was gliosarcoma. Gliosarcomas have a worse prognosis in terms of survival. Clinically, it is not possible to distinguish between glioblastomas and gliosarcomas. Treatment proceeds in the same way. © 2024 Ondokuz Mayis Universitesi. All rights reserved.en_US
dc.identifier.doi10.52142/omujecm.41.1.25
dc.identifier.endpage154en_US
dc.identifier.issn1309-4483
dc.identifier.issn1309-5129
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85189521271
dc.identifier.scopusqualityQ4
dc.identifier.startpage152en_US
dc.identifier.urihttps://doi.org/10.52142/omujecm.41.1.25
dc.identifier.urihttps://hdl.handle.net/20.500.12712/37367
dc.identifier.volume41en_US
dc.language.isoenen_US
dc.publisherOndokuz Mayis Üniversitesien_US
dc.relation.ispartofJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrain Tumoren_US
dc.subjectGlioblastomaen_US
dc.subjectGliosarcomaen_US
dc.subjectIsocitrate Dehydrogenaseen_US
dc.titleA Rare Variant of Glioblastoma Is Gliosarcoma: 11-Case Clinical Trialen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files